Table 4.
Mean lipid changes from baseline to week 48 in the SINGLE study
| Parameter | Treatment | Baseline | Change from baseline | Maximum post-baseline emergent grade 2–4 elevationsa | ||
|---|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) | n/N (%) | ||
| TC (mg/dL) | DTG | 346 | 158.9 (34) | 296 | 17.1 (26) | 35/414 (8) |
| EFV | 355 | 158.2 (37) | 279 | 24.1 (34) | 32/419 (8) | |
| LDL-C (mg/dL) | DTG | 342 | 93.1 (29) | 289 | 8.5 (21) | 32/414 (8) |
| EFV | 353 | 92.7 (22) | 273 | 13.1 (30) | 24/419 (6) | |
| HDL-C (mg/dL) | DTG | 346 | 43.4 (13) | 296 | 5.2 (9) | NA |
| EFV | 355 | 43.6 (13) | 279 | 8.0 (11) | NA | |
| TC:HDL ratio | DTG | 374 | 3.9 (1) | 320 | −0.1 (1) | NA |
| EFV | 381 | 3.9 (1) | 302 | −0.1 (1) | NA | |
| Triglycerides (mg/dL) | DTG | 346 | 115.0 (78) | 296 | 17.7 (94) | 8/414 (2) |
| EFV | 355 | 111.2 (67) | 279 | 18.6 (92) | 9/419 (2) | |
DAIDS Division of AIDS, DTG dolutegravir, EFV efavirenz, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NA not applicable, SD standard deviation, TC total cholesterol
aDAIDS grading system